ArticleESMO real world data and digital oncology2025
JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma.Current oncology (Toronto, Ont.) · 2026Observational
- Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.International journal of urology : official journal of the Japanese Urological Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avelumab maintenance therapy was approved in Japan in February 2021 for patients with unresectable locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression after platinum-based chemotherapy (PBC). We report the primary analysis from the JAVEMACS chart review study of avelumab maintenance therapy in Japan. Materials and methods: This multicenter, retrospective study collected data from medical charts of patients with la/mUC who received avelumab maintenance after first-line (1L) PBC. Results: Between February 2021 and December 2023, 350 patients received avelumab maintenance; median age was 73 years and most were male (74.0%). Prior 1L PBC was cisplatin-gemcitabine in 56.0% and carboplatin-gemcitabine in 33.1%; 28.6% were cisplatin eligible and 52.9% were cisplatin ineligible/platinum eligible. At data cut-off (June 2024), 67 patients (19.1%) were still receiving avelumab. Among 283 patients who discontinued avelumab, 200 (70.7%) received second-line (2L) treatment. In the overall population, median overall survival (OS) from avelumab initiation was 31.8 months [95% confidence interval (CI) 24.6 months-not estimable (NE)]. In subgroups who received 2L enfortumab vedotin (EV) ( Conclusions: Results from JAVEMACS confirm the effectiveness of avelumab maintenance in real-world clinical practice in Japan, supporting its recommendation for patients with la/mUC without disease progression following 1L PBC. This treatment sequence followed by 2L EV appeared to be associated with encouraging long-term outcomes in this real-world population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.